Company Overview
FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.32.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -85.48% |
| 6 Months: | -78.62% |
| 3 Months: | +69.31% |
| 1 Month: | +75.20% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)61.88 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 86.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | FBLG FibroBiologics, Inc. PHARMA | 1.71 | -0.34 | $11.39M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.27M | -2.09M | -2.05M | -3.45M | -3.22M | -3.35M | -4.53M | -4.49M | -5.04M | -5.07M | -4.03M |
| Net Income | -2.42M | -2.16M | -2.19M | -8.46M | 898.00K | -500.00K | -4.97M | -4.66M | -5.78M | -5.00M | -4.12M |
| Diluted EPS | -0.18 | -0.08 | -0.08 | -0.27 | 0.03 | -0.01 | -2.71 | -2.41 | -0.13 | -1.33 | -0.66 |
| R&D Expense | 478.00K | 547.00K | 571.00K | 960.00K | 975.00K | 1.21M | 1.78M | 2.04M | 2.79M | 2.95M | 1.66M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Income | -4.47M | -8.89M | -13.74M | -16.65M |
| Net Income | -5.12M | -16.48M | -11.16M | -18.65M |
| Diluted EPS | -0.18 | -0.68 | -0.34 | -0.42 |
| R&D Expense | 1.15M | 2.37M | 4.50M | 7.41M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 4.82M | 11.82M | 16.45M | 9.62M |
| Total Equity | -1.29M | -4.00M | 1.25M | 2.73M | 6.16M |
| Cash & Equivalents | - | 2.27M | 9.16M | 13.98M | 4.89M |
| Total Liabilities | - | 8.82M | 10.57M | 13.71M | 3.46M |
| Current Liabilities | - | 7.07M | 9.18M | 12.73M | 1.76M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -4.07M | -6.40M | -11.90M | -16.39M |
| Investing Cash Flow | - | -495.00K | -184.00K | -262.00K |
| Financing Cash Flow | 5.92M | 13.79M | 16.91M | 7.57M |
| Capital Expenditure | - | -495.00K | -184.00K | -262.00K |
| Free Cash Flow | - | -6.90M | -12.09M | -16.66M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | - | - | - | - |
| ROE % | 128.2% | -1,315.6% | -408.1% | -302.9% |
| ROCE % | 198.6% | -337.0% | -369.4% | -211.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cascade Financial Partners, LLC | 1.63% | 108.83K | $155.62K |
| 2 | Fund Evaluation Group, LLC | 0.78% | 51.79K | $74.06K |
| 3 | Geode Capital Management, LLC | 0.46% | 30.30K | $43.33K |
| 4 | Vanguard Capital Management LLC | 0.42% | 27.77K | $39.71K |
| 5 | Qube Research & Technologies Ltd | 0.37% | 24.31K | $34.77K |
| 6 | Blackrock Inc. | 0.27% | 18.24K | $26.08K |
| 7 | Barclays Plc | 0.11% | 7.24K | $10.36K |
| 8 | Vanguard Fiduciary Trust Co | 0.10% | 6.38K | $9.12K |
| 9 | Tower Research Capital LLC (TRC) | 0.07% | 4.73K | $6.76K |
| 10 | Osaic Holdings Inc. | 0.04% | 2.40K | $3.44K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for FBLG
In early tests, treated wounds healed significantly faster. FibroBiologics received a U.S. patent. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxQZE9GMTRpaVctME1YM0FEVkttcjhzckN6Q1p2MF9UcGdnRVhXRVI1emp4YUVDRzViRFloSjNWaEtNU2hLYmVmSEV2NVNScWxaclNDX1dfdjlXLUUwNGQ1dGUzRFByakNKTUVobTZPcXFJSzJkSUNGbWo1cDBPeHk0djI2Ylh5VzlBb1YxTG…
FIBROBIOLOGICS ($FBLG) Releases Q2 2026 Earnings - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxObTZ4c3lyQ0NYVVFPQjNvOGxUUFFPYWpDUVBpTWV6WXpZOXpvRWgyZVVDREVzb3dNbE9lVlRxY2N6S3lLc2I2VVljRmZWeGJlTFBnYkZNMllyVEdkN3NTc0hmZ3B2amlDYVlGSGt3TmdrZGJITlNyNm1rTnV3R1dGRnFmZzNXNUJ5Vkh4TF…
FBLG Forecast — Price Target — Prediction for 2027 - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE05ZEVCQ0IwTzUyS3VxWFJ2dlh0aDdlTThwdXQ1ci0weWtkUzBZQ3pBcndwRGlCQWhrbDhkZE1leDRUQW5Sel95b2ZjMGJNV3N6SkctVHdDMFBuMlAzQ1NLbjcxcjhjdW1FR3lHd2owRThYWVVBRW4zb1h3?oc=5" target="_blank">FBL…
FBLG - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBxSHp2RTF3bFNHaklpWjBMRHZoX2JTOUZ0aTdlVUdNcmN4X2JvWmYzN3NyaDlQUW0tWlUyS0gtVlpINzlleHc?oc=5" target="_blank">FBLG</a> <font color="#6f6f6f">Finviz</font>…
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOdmxtSnV5d3g5b1Nsbmw1dHFjbWd6ZnVMTkRTU3gwdXYzUjVWRkdwTlZxRVA2aGJaREVuZHM2ZXV1UlBaR2RXQmpUMXFtR1Z0OWlicWpkZWkyUFRvQ3JfVDVTd0lIVlgzcVZtYnVqN1pESkxLeXVxN1hMQ1JZY1ZPMS1ZNk1rZUFma2pqZ1…
FibroBiologics (NASDAQ: FBLG) appeals Nasdaq move to delist its shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxPdHFRYmx5ZVNWbFlmNmUtVm5qS3FBRTFKZ2w1THN4Y2FxWTVqMHI5N1FldGxQY04xSi0yYW9HNzBCY1h2NVZTRXFTcWN5Z2ZRWmhzR0d5bVYyUWxPOFdYRkI3QTZFRjliT3gyMWU2OWhPNEoxTHE5QWpMblpKVHZ4VTdRcXpseWVnVVVTZ0…
FBLG — Frequently Asked Questions
What is the current share price of FibroBiologics, Inc. (FBLG)?
As of 2026-09-19 21:16 PDT, FibroBiologics, Inc. (FBLG) trades at $1.71 on NasdaqCM. Its 52-week range is $0.63 to $12.42.
What is the market capitalisation of FBLG?
FibroBiologics, Inc. (FBLG) has a market capitalisation of $11.39M on NasdaqCM.
What is the P/E ratio of FBLG?
FBLG trades at a trailing price-to-earnings (P/E) ratio of -0.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.31.
Is FBLG a good stock to buy?
This page provides a data-driven analysis of FibroBiologics, Inc. (FBLG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.